Not an official events of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation
Saturday, May 30, 2026
7:00 p.m. – 8:30 p.m. CT
Please note this virtual program is at 8:00 p.m. Eastern, 7:00 p.m. Central, 6:00 p.m. Mountain and 5:00 p.m. Pacific.
FACULTY
 |
Brian Slomovitz, MD Director, Gynecologic Oncology Mount Sinai Medical Center Miami Beach, Florida |
PROGRAM OVERVIEW
This virtually live ASCO program provides oncologists, APPs, nurses, pharmacists, and clinicians with a comprehensive update on the rapidly evolving treatment landscape of ovarian cancer. Participants will explore the structure, mechanism of action, and therapeutic rationale behind recently approved and emerging agents, including antibody-drug conjugates (ADCs), glucocorticoid receptor modulators, and bispecific antibodies. Through a detailed analysis of the latest clinical trial safety and efficacy data alongside updated guidelines, the session focuses on practical strategies for integrating these novel therapies into clinical practice using shared decision-making. Additionally, the program offers expert guidance on proactively monitoring and managing unique adverse events, ensuring clinicians are equipped to optimize patient outcomes and safety in the modern era of precision oncology.
LEARNING OBJECTIVES
- Describe the structure, mechanism of action, and therapeutic rationale, of recently approved and emerging agents in ovarian cancer
- Interpret clinical trial safety and efficacy data and recent guideline updates and employ shared decision making (SDM) to determine when and how to integrate recently approved and emerging therapies into treatment
- Explain how to monitor for and manage adverse events associated with ADCs, glucocorticoid receptor modulators, and bispecific antibodies for the treatment of ovarian cancer
TARGET AUDIENCE
The proposed education will be designed to meet the educational needs of gynecologic and medical oncologists, nurses, pharmacists, advanced practice providers, and other clinicians involved in the treatment of patients with gynecologic malignancies.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this virtually live activity for a maximum of up to 1.5 knowledge-based CPE contact hour.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
